The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Isoniazid for preventing tuberculosis in non-HIV infected persons
Open accessAbstract
BACKGROUND: Although isoniazid (INH) is commonly used for treating tuberculosis (TB), it is also effective as preventive therapy. OBJECTIVES: The objective of this review was to estimate the effect of 6 and 12 month courses of INH for preventing TB in HIV-negative people at increased risk of developing active TB. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group trials register, the Cochrane Controlled Trials Register, Medline, Embase and reference lists of articles. We hand-searched Science Citation Index and Index Medicus. SELECTION CRITERIA: Randomised trials of INH preventive therapy for 6 months or more compared with placebo. Follow-up for a minimum of 2 years. Trials enrolling patients with current or previously treated active TB, or with known HIV infection, were excluded. Criteria were applied by two reviewers independently. DATA COLLECTION AND ANALYSIS: Trial quality was assessed by two reviewers independently, and data extracted by one reviewer using a standardized extraction form. MAIN RESULTS: Eleven trials involving 73,375 patients were included. Trials were generally of high quality. Treatment with INH resulted in a relative risk (RR) of developing active TB of 0.40, (95% confidence interval ¿CI¿ 0.31 to 0.52), over two years or longer. There was no significant difference between 6 and 12 month courses (RR of 0.44, 95% CI 0.27 to 0.73 for six months, and 0.38, 95% CI 0.28 to 0.50 for 12 months). Preventive therapy reduced deaths from TB, but this effect was not seen for all cause mortality. INH was associated with hepatotoxicity in 0.36% of people on 6 months treatment and in 0.52% of people treated for 12 months. REVIEWER'S CONCLUSIONS: Isoniazid is effective for the prevention of active TB in diverse at-risk patients, and six and 12 month regimens have a similar effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Assessment of Clinically Useful Measures of the Consequences of Treatment
Laupacis, A., Sackett, D. L., & Roberts, R. S. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806303182605 · Cited by 1,681
Bass, J. B., Farer, L. S., Hopewell, P. C., O'Brien, R., Jacobs, R. F., Ruben, F., Snider, D. E., & Thornton, G. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.5.8173779 · Cited by 1,193
The global tuberculosis situation and the new control strategy of the World Health Organization
Kochi, A. (1991) · Tubercle · doi:10.1016/0041-3879(91)90017-m · Cited by 843
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Iuat (1982) · Bulletin of the World Health Organization · Cited by 515
Using Numerical Results from Systematic Reviews in Clinical Practice
McQuay, H. J., & Moore, R. A. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-9-199705010-00007 · Cited by 455
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)91817-6 · Cited by 441
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Control and prevention of tuberculosis in the United Kingdom: Code of Practice 2000
Joint Tuberculosis Committee of the British Thoracic Society (2000) · Thorax · doi:10.1136/thorax.55.11.887 · Cited by 366
Hong Kong Chest Service/Tuberculosis Research Centre, M. M. R. C. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.1.36 · Cited by 304
Crossley, P. E. L. (1954) · International Journal of Dairy Technology · doi:10.1111/j.1471-0307.1954.tb00809.x · Cited by 259
Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies.
Comstock, G. W., Baum, C., & Snider, D. E. (1979) · PubMed · doi:10.1164/arrd.1979.119.5.827 · Cited by 241
(1982) · Europe PMC (PubMed Central) · Cited by 236
A controlled trial of community-wide isoniazid prophylaxis in Alaska.
Comstock, G. W., Ferebee, S. H., & Hammes, L. M. (1967) · PubMed · doi:10.1164/arrd.1967.95.6.935 · Cited by 211
Barnes, P. F., & Barrows, S. A. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-5-199309010-00009 · Cited by 201
Isoniazid-associated Hepatitis Deaths: A Review of Available Information
Snider, D. E., & Caras, G. J. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.2_pt_1.494 · Cited by 199
Ferebee, S. H., & MOUNT, F. W. (1962) · PubMed · doi:10.1164/arrd.1962.85.4.490 · Cited by 187
Gordin, F. M., Matts, J. P., Miller, C., Brown, L. S., Hafner, R., John, S. L., Klein, M., Vaughn, A., Besch, C. L., Perez, G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370505 · Cited by 166
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults
Hawken, M. P., Meme, H., Elliott, L. C., et al. (1997) · AIDS · doi:10.1097/00002030-199707000-00006 · Cited by 141
Hsu, K. H. K. (1984) · JAMA · doi:10.1001/jama.1984.03340340023018 · Cited by 124
Rose, D. N. (1986) · JAMA · doi:10.1001/jama.1986.03380190079029 · Cited by 105
A controlled trial of isoniazid prophylaxis in mental institutions
Ferebee, S. H., MOUNT, F. W., Murray, F. J., & Livesay, V. T. (1964) · Nursing Research · doi:10.1097/00006199-196401320-00046 · Cited by 91
Preventive therapy for tuberculosis
Bess, M. (1993) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30192-4 · Cited by 84
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
Salpeter, S. R. (1993) · PubMed Central · Cited by 84
John, G. T., Thomas, P. P., Thomas, M., Jeyaseelan, L., Jacob, C. K., & Shastry, J. C. M. (1994) · PubMed · Cited by 78
John, G. T., Thomas, P. P., Thomas, M., Jeyaseelan, L., Jacob, C. K., & Shastry, J. C. M. (1994) · Transplantation · doi:10.1097/00007890-199457110-00029 · Cited by 78
Gj, V. (1968) · PubMed · Cited by 46
Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.
HORWITZ, O., Pg, P., & Wilbek, E. (1966) · PubMed · Cited by 46
Preventive Treatment of Untreated, Nonactive Tuberculosis in an Eskimo Population
Comstock, G. W., & Woolpert, S. F. (1972) · Archives of Environmental Health An International Journal · doi:10.1080/00039896.1972.10666182 · Cited by 37
Decision Analysis for Isoniazid Preventive Therapy: Take It or Leave It?
Snider, D. E. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/137.1.2 · Cited by 35
Debre, R., Perdrizet, S., Lötte, A., NAVEAU, M., & Lert, F. (1973) · International Journal of Epidemiology · doi:10.1093/ije/2.2.153 · Cited by 34
Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial.
Grzybowski, S., Ashley, M., & Pinkus, G. (1976) · PubMed · Cited by 28
Vandiviere, H. M., Dworski, M., Melvin, I. G., et al. (1973) · PubMed · doi:10.1164/arrd.1973.108.2.301 · Cited by 26
Isoniazid prophylaxis among Alaskan Eskimos: a progress report.
Comstock, G. W., Woolpert, S. F., & Baum, C. (1974) · PubMed · doi:10.1164/arrd.1974.110.2.195 · Cited by 24
Further Developments in Human and Bovine Antituberculosis Chemoprophylaxis with Isoniazid in Italy
ZORINI, A. O. (1963) · Diseases of the Chest · doi:10.1378/chest.43.2.131 · Cited by 5
Cited by
Towards tuberculosis elimination: an action framework for low-incidence countries
Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., de Vries, G., Diel, R., Douglas, P., Falzon, D., Gaudreau, M.-A., Goletti, D., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00214014 · Cited by 778
Latent Mycobacterium tuberculosis Infection
Getahun, H., Matteelli, A., Chaisson, R. E., & Raviglione, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1405427 · Cited by 775
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
Evidence-based clinical guidelines for immigrants and refugees
Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N. E., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 526
Balk, E. M. (2002) · JAMA · doi:10.1001/jama.287.22.2973 · Cited by 478
Metadata
- Authors
- Smieja, M., Marchetti, C., Cook, D., & Smaill, F. M.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 1999-01-25
- Volume
- 2019
- Issue
- 5
- Pages
- CD001363-CD001363
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1930781376
- Cited by
- 434
- References
- 37
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.